The role of zoledronic acid in the adjuvant treatment of breast cancer: Current perpectives

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2715-2725

  Tonyali, Onder ^a   Arslan, Cagatay ^b   Altundag, Kadri ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adjuvant treatment; Breast cancer; Zoledronic acid

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CASPASE 3; CLODRONIC ACID; DOCETAXEL; DOXORUBICIN; GOSERELIN; GUANOSINE TRIPHOSPHATASE; IBANDRONIC ACID; IMATINIB; LETROZOLE; LYMPHOCYTE ANTIGEN RECEPTOR; MATRIX METALLOPROTEINASE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UFT; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; BONE DENSITY; BONE MATRIX; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CELL INVASION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; HUMAN; META ANALYSIS; MORTALITY; OSTEOCLAST; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMIDAZOLES;

EID: 78049362725     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.523699     Document Type: Review

References (73)

1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures, 2007. American Cancer Society, Atlanta
2. Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis\optimizing efficacy in clinical practice. Clin Interv Aging 2008;3:279-97
3. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11(1):59-65
4. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;12:2007-11
5. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-7
6. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006;8:R13
7. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008;112:1001-10
8. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozoleinduced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol 2008;9:840-9
10. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormoneresponsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8
11. Brufsky AM, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9(2):77-85
12. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30
13. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78
14. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-8
15. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453-75
16. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
17. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87
18. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-73
19. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
20. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78
21. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
22. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
23. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
24. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human (gamma, delta) T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67(15):7450-7
25. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54
26. Denoyelle C, Hong L, Vannier JP, et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects. Br J Cancer 2003;88:1631-40
27. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-4
28. Van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705
29. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60(11):2949-54
30. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21
31. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68
32. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007;246:308-12
33. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-86
34. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34
35. Santini D, Martini F, Fratto M, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.Cancer Immunol Immunother 2009;58:31-8
36. Yuasa T, Kimura S, Ashihara E, et al. Zoledronic acid-a multiplicity of anticancer action. Curr Med Chem 2007;14:2126-35
37. Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonize bone growth factors' effects on human breast cancer cells survival. Br J Cancer 2003;89:178-84
38. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-67
39. Coscia M, Quaglino E, Lezzi M, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2009. DOI: 10.1111/j.1582-4934.2009. 00926.x 2009
40. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001;28:35-44
41. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63
42. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year followup followup of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650-6
43. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomized comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47:740-6
44. Kokufu I, Kohno N, Takao S, et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes. ASCO (Ann Meeting Proc) 2004;22(14S):abstract 530
45. Jung J, Hwang G, Lee Y, et al. Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer [abstract 888]. J Clin Oncol 2005;23(16S):99s
46. Gnant M, Mlineritsch B, Schippinger W, et al.; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
47. Gnant MB, Stoeger MH, Luschin-Ebengreuth G, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010;28(15s):abstract 533
48. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70
49. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
50. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
51. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; Doi:10. 1093/anon/mdq217
52. Eidtmann H, Bundred N, Deboer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. In: CTRC-AACR San Antonio breast cancer symposium. Cancer Research, San Antonio, USA; 2008
53. Lombarto L, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. ASCO 2009 Breast Cancer Symposium Abstract No:213
54. Coleman R, Bundred N, De Boer R, et al. Impact of ZOL in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-Z-FAST, Cancer Res 2009;69(24):733s
55. Coleman RE, Winter MC, Cameron D, et al.; AZURE (BIG01/04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105
56. Mauri D, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010;8(3):279-86
57. Aebi S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v9-14
58. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6
59. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
60. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26
61. Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 2007;(Suppl 1):29-35
62. Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract 559]. J Clin Oncol 2008;26(Suppl):20s
63. Rack B, Schindlbeck C, Strobl B, et al. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008;133:285-9
64. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract 2048]. Cancer Res 2009;69(Suppl 2):170s-1s
65. Mauri D, Valachis A, Polyzos NP, et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw 2010;8:279-86
66. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003;106:973-9
67. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects ofST1571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-15
68. Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86
69. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9
70. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005;16:845-54
71. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113:364-71
72. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103
73. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004;12:1109-14